Monogram Biosciences, Inc.

Ellen Paxinos

Neil T Parkin

Signe Fransen

Soumi Gupta

Christos J Petropoulos

Mary T Wrin

Colombe Chappey

Andrea Gamarnik

This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus ('HIV') to the non-nucleoside reverse transcriptase inhibitors ('NNRTIs') efavirenz (&#x201c;EFV&#x201d;), nevirapine (&#x201c;NVP&#x201d;), and delavirdine (&#x201c;DLV&#x201d;), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.

Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs

The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir

Growing community of inventors

San Jose, CA, United States of America

Ellen Paxinos